Cerecor to Present at Biotech Showcase 2012 in San Francisco
Company to Present Overview and Update on Development Milestones
(firmenpresse) - BALTIMORE, MD -- (Marketwire) -- 01/05/12 -- Cerecor Inc., a biopharmaceutical company focused on the whose primary activity is in the human brain, today announced that Blake M Paterson, M.D., Co-founder & CEO of Cerecor, will present at the Biotech Showcase 2012 Conference. Cerecor's lead candidate, FP01, is a treatment for cough. In a proof-of-concept study in humans, academic investigators demonstrated a significant treatment effect. Dr. Paterson plans to discuss the recently finalized formulation of FP01 as well as Cerecor's plan to begin clinical trials in the second quarter of 2012.
Dr. Paterson will make a presentation to prospective corporate partners and investors on Monday, January 9th at 10:00 AM PST. The Company's presentation will be delivered at the Parc 55 Wyndham Hotel in San Francisco.
In addition, Dr. Paterson will be available throughout the event for one-on-one meetings with investors by appointment only. To schedule a meeting, registered attendees can submit a meeting request through the conference website ().
The Biotech Showcase is a forum devoted to enable private and public life science companies the opportunity to present to an audience of investors and business development executives. Now in its fourth year, this rapidly growing financial-focused biotech conference features multiple tracks of presenting companies, plenary sessions, an opportunity to schedule one-on-one partnering meeting and networking.
Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the whose primary activity is in the human brain. We are a Delaware corporation, organized in April 2011 in partnership with various laboratories and research institutes at Johns Hopkins Medical Institute ("JHMI"). Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. We acquire rights to early stage therapeutic technologies ("assets") from universities, finance and manage the development of these assets into drug candidates (to a significant milestone or a major value inflection point) and then out license the asset for commercialization to a partner.
Jeff Ramson
ProActive Capital Resources Group
(215) 717-4104
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.01.2012 - 12:55 Uhr
Sprache: Deutsch
News-ID 1070404
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BALTIMORE, MD
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 95 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cerecor to Present at Biotech Showcase 2012 in San Francisco
"
steht unter der journalistisch-redaktionellen Verantwortung von
Cerecor Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
